{"ticker": {"uuid": "95ec0423-02a6-4ee0-a560-c822ff1bf36c", "symbol": "NP5", "name": "Newron Pharmaceuticals S.p.A.", "exchange": "GER", "country": "DE", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Newron Provides Update Following Type A Meeting With the FDA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQWmxTOEJwZnVHbzdLZkdOUFVPMTJ4N3JzRVY0eVRDNXA1d1hOMGtaWm5KbUloOXNvWHZ1Z0tuS2VmSnFsYlNDUHk3VXAwWE5GS2QwZDZHWFRzRkQ1T1JKLUQ1X0dyZ3k3YnZSWHRZc2lOdnl0T2F6Uy1XYzdlVHRrajhxa2NNQVdsYklKb1BEWjZ1X2UwbTByNWlERldIWVBrc2JFZkxWUkdsZzluVjd4Y0xnazJKV180?oc=5", "source_name": "Business Wire", "published_at": "2026-07-02T15:45:00+00:00", "published_display": "02 Jul 2026 15:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Newron Pharmaceuticals to Participate in June Investor Conferences", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxONVd5NWk1WXY3Yl9LTzZ2S3RJOXpKNnVPSHJfVUtKWUh5dmlLNk1ZOW5iRXh5RERCZjhYSVJTVzNxWndjcF9SaVU2cjJKQ2xGZm9VT0dOY0lPaFNWRm9PRG1LTV9XbTlXcERKcGVyTS1QT3FjWUI2YTEwRHpmQnU1aXB6ZTFmN05Ua0tBYk0xVVgxUFlYSWx5Q0FINTRYUEJJNXIyNDI2VzhCWUcwZlh4WW9IU2NoSFhWclZBaTJKMkY?oc=5", "source_name": "Business Wire", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Newron Reports a Pause of Enrollment of New Study Participants in US Centers of ENIGMA-TRS 2 Study", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxOSnJHNnptdEFWRzdaaVJUX3NKYnhMVGEyTlBQbC1ldklQbUNqeVFpOTdUN0hua2c1dWFfUldqN2dDQTE1cXo2dHJfTXdfRW5mOTAyNWROd1BMcVd5RzFSNVVweGxpX1BrbWZDZnJydkM3X05yeXZabFlFeXRYOWdDZWNCaWpHeXZLVTdNMVc1akFLbGNqamJLeFlyNGF6SmNNYTJGX1Y0VndmZTRfQXZDQWdHdzZERzJjOXVmVVN1M3hUQld5aktwX09fOFVvYTl1OEcxdF80M1huNUhDN1FLMGFTejBtR0g2M0lj?oc=5", "source_name": "Business Wire", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Newron Secures Up to EUR 38 Million to Advance Phase III Evenamide Program", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQRVVUOWQ4S3FiZUFCMkwwWld2UE1ldWJ2ZTJEdlNVS05Wd2hRbTMtZVh1Sk1Ma2s3cE1wS0RGMDFLTzFBb2lKdEs1TzE0UjVGdExYUUQtM3FGM0lkUE10T29xNi1zbUhTQ0NzNF9jSEVkSW5RUkFub3ctX2EtZUxLWHBQSXZLR1lydkZFUWtEY3FlZGNoZmNmMnBYWEpUcEluQklabGpWeG1RQjFzSERhOWhIVTk3T1RFM2NjeGp1UFhMRWtBSWVkbC1aMA?oc=5", "source_name": "Business Wire", "published_at": "2026-02-16T08:00:00+00:00", "published_display": "16 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Newron Announces Approval for Pivotal Phase III ENIGMA-TRS Program With Evenamide as Add-on Therapy in Patients With Treatment-resistant Schizophrenia (TRS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwJBVV95cUxPdlJjQ25Tck9lM1MwT3NlUE8wZVFROXpZcFpSM3lISzdoR1FMNER2cURHNXRlcXpvYnpQQVJHNlNKd2gtQ0l2VWk4U1RWVm1hbnZJNzZJd0RETVRENUpwM1FpcHhFc1MxQlE4TGxmVGRwdHdKNXFEUHY1TWwwWnFnNmFmNDBJcjFCNmM5UlpZY0VLbUhmR1RNVEptMW9wc2dfVEZLaGQ1QjBJbHpfSldNN01SOEpBUWg4ZFFwLWJLTERGU3lsYXoxdmRjaTNEd2xoM2l4LUItcExpZEF1MEJ5V0xIR2Y3RzFKenNCRURoWGxFb19KUzdkc1N0VW1fX1NzWElkRjlkaFpvckJaN1JYN0doemQ0T25fVVJVQUc3Yw?oc=5", "source_name": "BioSpace", "published_at": "2025-05-12T07:00:00+00:00", "published_display": "12 May 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQTnRKb0RleVZPT1M5cGtDZF8tVDhjemxOdi1jaEhHUGQ2MFhMbElfZ1c2VUNEY3FoVkMyOE5RaDc3NXRMSjBDWERZMVZDV01VeldwUGhZaTNoMzZuTVhGTXJ5emdRc1dST0hZNGtqV2Iybnh0Z1RfSkdOOVdUWnZ6Z0s5d2ZJRTFVUTctVmNrN1pVbzdQbFNyN08yQzZSZllRTWpHOW10eEJMdkJmZkthT2xYR3lKelhlUjk2SDNyZ1RXRDhSWlB2Q05R?oc=5", "source_name": "Business Wire", "published_at": "2024-06-18T07:00:00+00:00", "published_display": "18 Jun 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Newron Announces 2022 Financial Results and Provides Outlook For 2023", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPcHRwaUpMVzAtdjh4VVRoWll5QTE3Vk04Qjg1YV9ONmw5NUttWGxKN1NoRTAyT1gxNEVKOFREeUVSOS1BWm91ZTR2Qlh6dVY4clRhbkpSUld0dV9oVVR0X1RSX1NlQ0MxdnlKUVZBQm9Bb29IYTZQN0M0T21OdG1oRW93QXdnbUtqNnI1M2oxTzBjdUZSN3prajMxd3ZNa2hjYjExT0ZmTlNib1ppazd5SV9oN3Z3MEpJQzZiemJSODF2VkNB?oc=5", "source_name": "Business Wire", "published_at": "2023-03-14T07:00:00+00:00", "published_display": "14 Mar 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Newron Provides Update Following Type A Meeting With the FDA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQWmxTOEJwZnVHbzdLZkdOUFVPMTJ4N3JzRVY0eVRDNXA1d1hOMGtaWm5KbUloOXNvWHZ1Z0tuS2VmSnFsYlNDUHk3VXAwWE5GS2QwZDZHWFRzRkQ1T1JKLUQ1X0dyZ3k3YnZSWHRZc2lOdnl0T2F6Uy1XYzdlVHRrajhxa2NNQVdsYklKb1BEWjZ1X2UwbTByNWlERldIWVBrc2JFZkxWUkdsZzluVjd4Y0xnazJKV180?oc=5", "source_name": "Business Wire", "published_at": "2026-07-02T15:45:00+00:00", "published_display": "02 Jul 2026 15:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Newron Pharmaceuticals to Participate in June Investor Conferences", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxONVd5NWk1WXY3Yl9LTzZ2S3RJOXpKNnVPSHJfVUtKWUh5dmlLNk1ZOW5iRXh5RERCZjhYSVJTVzNxWndjcF9SaVU2cjJKQ2xGZm9VT0dOY0lPaFNWRm9PRG1LTV9XbTlXcERKcGVyTS1QT3FjWUI2YTEwRHpmQnU1aXB6ZTFmN05Ua0tBYk0xVVgxUFlYSWx5Q0FINTRYUEJJNXIyNDI2VzhCWUcwZlh4WW9IU2NoSFhWclZBaTJKMkY?oc=5", "source_name": "Business Wire", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Newron Reports a Pause of Enrollment of New Study Participants in US Centers of ENIGMA-TRS 2 Study", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxOSnJHNnptdEFWRzdaaVJUX3NKYnhMVGEyTlBQbC1ldklQbUNqeVFpOTdUN0hua2c1dWFfUldqN2dDQTE1cXo2dHJfTXdfRW5mOTAyNWROd1BMcVd5RzFSNVVweGxpX1BrbWZDZnJydkM3X05yeXZabFlFeXRYOWdDZWNCaWpHeXZLVTdNMVc1akFLbGNqamJLeFlyNGF6SmNNYTJGX1Y0VndmZTRfQXZDQWdHdzZERzJjOXVmVVN1M3hUQld5aktwX09fOFVvYTl1OEcxdF80M1huNUhDN1FLMGFTejBtR0g2M0lj?oc=5", "source_name": "Business Wire", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Newron Secures Up to EUR 38 Million to Advance Phase III Evenamide Program", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQRVVUOWQ4S3FiZUFCMkwwWld2UE1ldWJ2ZTJEdlNVS05Wd2hRbTMtZVh1Sk1Ma2s3cE1wS0RGMDFLTzFBb2lKdEs1TzE0UjVGdExYUUQtM3FGM0lkUE10T29xNi1zbUhTQ0NzNF9jSEVkSW5RUkFub3ctX2EtZUxLWHBQSXZLR1lydkZFUWtEY3FlZGNoZmNmMnBYWEpUcEluQklabGpWeG1RQjFzSERhOWhIVTk3T1RFM2NjeGp1UFhMRWtBSWVkbC1aMA?oc=5", "source_name": "Business Wire", "published_at": "2026-02-16T08:00:00+00:00", "published_display": "16 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Newron Announces Approval for Pivotal Phase III ENIGMA-TRS Program With Evenamide as Add-on Therapy in Patients With Treatment-resistant Schizophrenia (TRS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwJBVV95cUxPdlJjQ25Tck9lM1MwT3NlUE8wZVFROXpZcFpSM3lISzdoR1FMNER2cURHNXRlcXpvYnpQQVJHNlNKd2gtQ0l2VWk4U1RWVm1hbnZJNzZJd0RETVRENUpwM1FpcHhFc1MxQlE4TGxmVGRwdHdKNXFEUHY1TWwwWnFnNmFmNDBJcjFCNmM5UlpZY0VLbUhmR1RNVEptMW9wc2dfVEZLaGQ1QjBJbHpfSldNN01SOEpBUWg4ZFFwLWJLTERGU3lsYXoxdmRjaTNEd2xoM2l4LUItcExpZEF1MEJ5V0xIR2Y3RzFKenNCRURoWGxFb19KUzdkc1N0VW1fX1NzWElkRjlkaFpvckJaN1JYN0doemQ0T25fVVJVQUc3Yw?oc=5", "source_name": "BioSpace", "published_at": "2025-05-12T07:00:00+00:00", "published_display": "12 May 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQTnRKb0RleVZPT1M5cGtDZF8tVDhjemxOdi1jaEhHUGQ2MFhMbElfZ1c2VUNEY3FoVkMyOE5RaDc3NXRMSjBDWERZMVZDV01VeldwUGhZaTNoMzZuTVhGTXJ5emdRc1dST0hZNGtqV2Iybnh0Z1RfSkdOOVdUWnZ6Z0s5d2ZJRTFVUTctVmNrN1pVbzdQbFNyN08yQzZSZllRTWpHOW10eEJMdkJmZkthT2xYR3lKelhlUjk2SDNyZ1RXRDhSWlB2Q05R?oc=5", "source_name": "Business Wire", "published_at": "2024-06-18T07:00:00+00:00", "published_display": "18 Jun 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Newron Announces 2022 Financial Results and Provides Outlook For 2023", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPcHRwaUpMVzAtdjh4VVRoWll5QTE3Vk04Qjg1YV9ONmw5NUttWGxKN1NoRTAyT1gxNEVKOFREeUVSOS1BWm91ZTR2Qlh6dVY4clRhbkpSUld0dV9oVVR0X1RSX1NlQ0MxdnlKUVZBQm9Bb29IYTZQN0M0T21OdG1oRW93QXdnbUtqNnI1M2oxTzBjdUZSN3prajMxd3ZNa2hjYjExT0ZmTlNib1ppazd5SV9oN3Z3MEpJQzZiemJSODF2VkNB?oc=5", "source_name": "Business Wire", "published_at": "2023-03-14T07:00:00+00:00", "published_display": "14 Mar 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 63, "total_relevant": 7, "sentiment_summary": {"positive": 0, "negative": 0, "neutral": 7, "score": 50, "total": 7, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 2.75, "count": 5}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "earnings", "label": "Earnings", "weight": 0.55, "count": 1}], "positive_events": 0, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 13.05, "latest_week": "2026-07-10", "one_week_move": -1.9, "four_week_move": -0.8, "twelve_week_move": -27.5, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.79318, "market_dynamics_buy_signal": false, "relative_strength": -21.908561, "fair_value_gap": 22.2, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 47.6259, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-1.9% over one week, -0.8% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 57, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Business Wire", "count": 6}, {"label": "BioSpace", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 7}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 5}, {"label": "Regulatory and legal", "count": 1}, {"label": "Earnings", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "7", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-1.9% over one week, -0.8% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Newron Provides Update Following Type A Meeting With the FDA"}], "updated_at": "2026-07-17T19:26:22.423128+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}